SEATTLE & CAMBRIDGE & TOKYO--(BUSINESS WIRE)--Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced it has been selected as “Regenerative Therapeutics Company of the Year” in the third annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe..

SEATTLE＆CAMBRIDGE＆TOKYO-（BUSINESS WIRE）-Aurion Biotech的使命是恢复数百万改变生命的再生疗法患者的视力，今天宣布它被选为“年度再生疗法公司”。生物技术突破开展的第三个年度生物技术突破奖计划，一个领先的独立市场情报组织，负责评估和认可全球杰出的生命科学和生物技术公司，产品和服务。。

Aurion Biotech is a clinical stage company that is developing a novel cell therapy to treat patients with corneal endothelial disease, which affects more than 16 million people throughout the world. Its cell therapy procedure is accessible for ophthalmologists, involving a single administration into the anterior chamber of the patient’s eye..

Aurion Biotech是一家临床阶段公司，正在开发一种新型细胞疗法来治疗角膜内皮疾病患者，该疾病影响全球超过1600万人。眼科医生可以使用其细胞治疗程序，只需向患者眼前房单次给药即可。。

The company’s proprietary manufacturing process enables it to reproduce fully differentiated corneal endothelial cells in vitro. Healthy cells from a single donor can be used to manufacture cells for more than 100 treatments. Additionally, this off-the-shelf, ready-to-use cell therapy does not require immune matching..

该公司专有的制造工艺使其能够在体外复制完全分化的角膜内皮细胞。来自单个供体的健康细胞可用于制造超过100次治疗的细胞。此外，这种现成的即用型细胞疗法不需要免疫匹配。。

Leveraging the pioneering inventions of Professor Shigeru Kinoshita, MD, of Kyoto Prefecture University of Medicine, Aurion Biotech has acquired the technology for further development. Earlier this year, the company received regulatory approval in Japan. In completed trials to date, 130 subjects have been treated in multiple studies involving multiple surgeons and diverse patient populations.

利用京都府立医科大学医学博士Shigeru Kinoshita教授的开创性发明，Aurion Biotech获得了该技术的进一步发展。今年早些时候，该公司在日本获得了监管部门的批准。在迄今为止完成的试验中，130名受试者在涉及多名外科医生和不同患者人群的多项研究中接受了治疗。

Subjects have experienced consistent, clinically meaningful and sustained improvements in key measures of corneal health. The company launched its U.S. Phase 1/2 trial (NCT06041256) this year..

受试者在角膜健康的关键措施方面经历了一致，临床意义和持续的改善。该公司今年推出了美国1/2期试验（NCT06041256）。。

“We are honored to be named BioTech Breakthrough’s ‘Regenerative Therapeutics Company of the Year,’” said Greg Kunst, Aurion Biotech’s CEO. “Receiving this recognition is another step in our effort to help millions of patients in need around the world.”

Aurion BioTech首席执行官Greg Kunst说：“我们很荣幸被评为生物技术突破年度的'再生治疗公司'。“获得这一认可是我们努力帮助全球数百万需要帮助的患者的另一步。”

The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the top companies, solutions and products in the life sciences and biotechnology industry today. This year’s program attracted more than 1,500 nominations from over 12 different countries throughout the world..

年度生物技术突破奖计划的使命是对当今生命科学和生物技术行业的顶级公司，解决方案和产品进行行业最全面的分析和评估。今年的节目吸引了来自全球12个不同国家的1500多项提名。。

“Aurion Biotech’s cell therapy has the potential to help restore vision to millions of underserved patients around the world suffering from corneal endothelial disease, a serious, sight-threatening and debilitating condition,” said Bryan Vaughn, Managing Director of BioTech Breakthrough Awards. “The current standard of care, corneal transplantation, is a complex surgical procedure which is difficult to perform and, currently, there's a severe worldwide shortage of donor corneas.

生物技术突破奖总经理布莱恩·沃恩（Bryan Vaughn）说：“Aurion Biotech的细胞疗法有可能帮助全世界数百万服务不足的患者恢复视力，这些患者患有角膜内皮疾病，这是一种严重的，威胁视力和使人衰弱的疾病。”。“目前的护理标准，角膜移植，是一种复杂的外科手术，难以执行，目前全球供体角膜严重短缺。

Aurion Biotech is advancing a game-changing single-dose cell therapy for this condition.”.

Aurion Biotech正在推进针对这种情况的改变游戏规则的单剂量细胞疗法。”。

About Aurion Biotech

关于Aurion Biotech

With offices in Seattle, Cambridge and Tokyo, Aurion Biotech is a clinical-stage biotech company, whose mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech is the recipient of the prestigious Prix Galien award for best start-up in biotech. The Company’s first candidate is for the treatment of corneal edema secondary to corneal endothelial disease, and is the first off-the-shelf, clinically validated cell therapy for corneal care, having received regulatory approval in Japan.

Aurion Biotech在西雅图，剑桥和东京设有办事处，是一家临床阶段的生物技术公司，其使命是通过改变生命的再生疗法为数百万患者恢复视力。Aurion Biotech是着名的Prix-Galien生物技术最佳初创企业奖的获得者。该公司的第一个候选人是治疗继发于角膜内皮疾病的角膜水肿，并且是第一个在日本获得监管部门批准的用于角膜护理的现成的临床验证的细胞疗法。

The Company has initiated clinical trials in the U.S. in 2023. Privately held, Aurion Biotech is backed by leading investors that include Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures. To learn more about Aurion Biotech, visit www.aurionbiotech.com.

该公司于2023年在美国启动了临床试验。私营的Aurion Biotech得到了包括Deerfield，Alcon，Petrichor，Fling L Partners，Falcon Vision/KKR和Visionary Ventures在内的领先投资者的支持。要了解有关Aurion Biotech的更多信息，请访问www.aurionbiotech.com。

About BioTech Breakthrough

关于生物技术的突破

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Food Science and BioAgriculture, and more.

部分技术突破是全球技术创新和领导力的领先市场情报和认可平台，生物技术突破奖计划致力于表彰生命科学和生物技术解决方案，服务和公司的卓越成就。生物技术突破奖为生物技术公司和产品在生物制药，基因组学，治疗学，食品科学和生物农业等领域的成就提供公众认可。

For more information visit BioTechBreakthroughawards.com.

欲了解更多信息，请访问biotechroughawards.com。

Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact.

Tech Breakput LLC不认可我们认可计划中描述的任何供应商，产品或服务，也不建议技术用户仅选择具有奖项名称的供应商。Tech Breakput LLC认可包括Tech Breakput LLC组织的意见，不应被解释为事实陈述。

Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose..

Tech Breakput LLC不承担本认可计划的所有明示或暗示保证，包括对适销性或适用于特定用途的任何保证。。